

CONTENTS

IMPORTANT NOTICE TO PROSPECTIVE [REDACTED]

This document is [REDACTED] by our Company solely in connection with the [REDACTED] and the [REDACTED] and does not constitute an [REDACTED] to sell or a solicitation of an [REDACTED] to buy any security other than the [REDACTED] [REDACTED] by this document pursuant to the [REDACTED]. This document may not be used for the purpose of making, and does not constitute, an [REDACTED] or invitation in any other jurisdiction or in any other circumstances. No action has been taken to permit a [REDACTED] of the [REDACTED] in any jurisdiction other than Hong Kong and no action has been taken to permit the distribution of this document in any jurisdiction other than Hong Kong. The distribution of this document for purposes of a [REDACTED] and the [REDACTED] and sale of the [REDACTED] in other jurisdictions are subject to restrictions and may not be made except as permitted under the applicable securities laws of such jurisdictions pursuant to registration with or authorization by the relevant securities regulatory authorities or an exemption therefrom.

You should rely only on the information contained in this document to make your [REDACTED] decision. The [REDACTED] is made solely on the basis of the information contained and the representations made in this document. We have not authorized anyone to provide you with information that is different from what is contained in this document. Any information or representation not contained nor made in this document must not be relied on by you as having been authorized by our Company, the Joint Sponsors, the [REDACTED], the [REDACTED], the [REDACTED], the [REDACTED], the [REDACTED] Intermediaries, any of the [REDACTED], any of our or their respective directors, officers, employees, agents or representatives of any of them or any other parties involved in the [REDACTED]. Information contained on our website (www.immuneonco.com) does not form part of this document.

	<i>Page</i>
Expected Timetable	i
Contents	iv
Summary	1
Definitions	30
Glossary of Technical Terms	41
Forward-Looking Statements	53
Risk Factors	55
Waivers from Strict Compliance with the Listing Rules and Exemption from Compliance with the Companies (Winding Up and Miscellaneous Provisions) Ordinance	112
Information about This Document and the [REDACTED]	119
Directors, Supervisors and Parties Involved in the [REDACTED]	123
Corporate Information	128

CONTENTS

Industry Overview	130
Regulatory Overview	167
History, Development and Corporate Structure	196
Business	226
Relationship with Our Controlling Shareholders	338
[REDACTED]	341
Share Capital	346
Substantial Shareholders	349
Directors, Supervisors and Senior Management	352
Financial Information	369
Future Plans and Use of [REDACTED]	410
[REDACTED]	413
Structure of the [REDACTED]	424
How to Apply for [REDACTED]	433
Appendix IA — Accountants’ Report	IA-1
Appendix IB — Unaudited Condensed Consolidated Financial Statements of the Group as of and for the Six Months Ended June 30, 2023	IB-1
Appendix II — Unaudited [REDACTED] Financial Information	II-1
Appendix III — Summary of Articles of Association	III-1
Appendix IV — Statutory and General Information	IV-1
Appendix V — Documents Delivered to the Registrar of Companies in Hong Kong and Available on Display	V-1